Clinical Trials
15 trialsNCT04164199 2026-06-03
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Completed
NCT05542342 2026-06-01
SITISVEAL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT03906071 2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3 Completed
NCT04887870 2025-10-10
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Mirati Therapeutics Inc.
Phase 2/3 Completed
NCT03015740 2024-11-19
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03666143 2024-11-04
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT03941873 2024-10-26
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
BeiGene
Phase 1/2 Completed
NCT04472650 2024-10-26
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
BeiGene
Phase 1 Completed
NCT02978859 2024-07-18
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Columbia University
Phase 2 Completed
NCT04518046 2024-06-05
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Mirati Therapeutics Inc.
Phase 1 Completed
NCT04887194 2024-05-08
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
Phase 1 Completed
NCT03680521 2023-10-04
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Mirati Therapeutics Inc.
Phase 2 Completed
NCT03575598 2023-07-27
SNOW
University Health Network, Toronto
Phase EARLY_PHASE1 Completed
NCT02219711 2023-03-06
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Mirati Therapeutics Inc.
Phase 1 Completed